CVM

#4465
Cel-Sci Corporation
4.3300 USD
+7.96%
版块: 医疗保健
基础: USD
利润货币: USD
日范围
4.1800
4.3300
年范围
3.0164
5.1500
日变化
+7.96%
每月变动
+20.28%
6个月变化
-15.92%
年变化
-15.92%
前一天收盘价
4.0106
开盘价
4.1800
买价
卖价
最低价
4.1800
High
4.3300
交易量
5
展开完整图表

Financials

概览 声明 统计
每季度 年度
  • Market Capitalization 36.623 M
  • Employee 44
  • Founded N/A
  • CEO N/A
  • Website www.cel-sci.com
  • Headquarter Colorado, United States
  • FIGI BBG000H5G6L5
  • Industry Technology
总收入
净利润
每股基本收益（基本 EPS）
总债务
自由现金流
现金及现金等价物
市盈率
-1.47
市销率
-57.5

Cel-Sci Corporation

Cel-Sci Corporation, is a biotechnology company that tests drugs for the treatment of cancer, autoimmune and infectious diseases through the research and development of immunotherapy products. Cel-Sci's main product is the drug Multikine, an immunotherapeutic agent designed to fight cancer by stimulating the body's immune system. Multikine is currently in Phase III of Clinical Trials with the Food and Drug Administration. Multikine has also been referred to as Leukocyte Interleukin Injection. Multikine was in Phase II testing of patients with head and neck cancer in the early 2000s, in which it demonstrated tumor-reducing ability. In January 2007, the US cleared the Phase 3 trial and Multikine was designated as an orphan drug by the FDA for neoadjuvant therapy of patients with squamous cell carcinoma of the head and neck. A total of 928 patients were enrolled in the head and neck cancer drug trial at that time. Subsequently, in June 2021, the company announced that the study missed its primary endpoint.

新闻